过氧化物酶体增殖物激活受体与血管生成——病理学意义。
PPARs and Angiogenesis-Implications in Pathology.
机构信息
Université Côte d'Azur, CNRS, INSERM, iBV, 06107 Nice, France.
出版信息
Int J Mol Sci. 2020 Aug 10;21(16):5723. doi: 10.3390/ijms21165723.
Abstract
Peroxisome proliferator-activated receptors (PPARs) belong to the family of ligand-activated nuclear receptors. The PPAR family consists of three subtypes encoded by three separate genes: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). PPARs are critical regulators of metabolism and exhibit tissue and cell type-specific expression patterns and functions. Specific PPAR ligands have been proposed as potential therapies for a variety of diseases such as metabolic syndrome, cancer, neurogenerative disorders, diabetes, cardiovascular diseases, endometriosis, and retinopathies. In this review, we focus on the knowledge of PPAR function in angiogenesis, a complex process that plays important roles in numerous pathological conditions for which therapeutic use of PPAR modulation has been suggested.
摘要
过氧化物酶体增殖物激活受体 (PPARs) 属于配体激活的核受体家族。PPAR 家族由三个独立基因编码的三种亚型组成：PPARα (NR1C1)、PPARβ/δ (NR1C2) 和 PPARγ (NR1C3)。PPARs 是代谢的关键调节剂，表现出组织和细胞类型特异性的表达模式和功能。特定的 PPAR 配体已被提议作为多种疾病的潜在治疗方法，如代谢综合征、癌症、神经退行性疾病、糖尿病、心血管疾病、子宫内膜异位症和视网膜病变。在这篇综述中，我们重点介绍了 PPAR 在血管生成中的功能知识，血管生成是一个复杂的过程，在许多病理条件下都发挥着重要作用，因此已经提出了使用 PPAR 调节来治疗这些疾病。
相似文献
1
PPARs and Angiogenesis-Implications in Pathology.过氧化物酶体增殖物激活受体与血管生成——病理学意义。
Int J Mol Sci. 2020 Aug 10;21(16):5723. doi: 10.3390/ijms21165723.
2
PPARs and Myocardial Infarction.过氧化物酶体增殖物激活受体与心肌梗死。
Int J Mol Sci. 2020 Dec 11;21(24):9436. doi: 10.3390/ijms21249436.
3
Peroxisome proliferator-activated receptors and inflammation.过氧化物酶体增殖物激活受体与炎症
Pharmacol Ther. 2006 Jun;110(3):371-85. doi: 10.1016/j.pharmthera.2005.08.007. Epub 2005 Sep 15.
4
The Role of PPARs in Disease.过氧化物酶体增殖物激活受体（PPARs）在疾病中的作用。
Cells. 2020 Oct 28;9(11):2367. doi: 10.3390/cells9112367.
5
Peroxisome proliferator-activated receptors and angiogenesis.过氧化物酶体增殖物激活受体与血管生成。
Nutr Metab Cardiovasc Dis. 2009 Dec;19(11):751-9. doi: 10.1016/j.numecd.2009.04.011. Epub 2009 Jul 23.
6
PPARs and angiogenesis.过氧化物酶体增殖物激活受体与血管生成。
Biochem Soc Trans. 2011 Dec;39(6):1601-5. doi: 10.1042/BST20110643.
7
[PPARs-mediated intracellular signal transduction].过氧化物酶体增殖物激活受体介导的细胞内信号转导
Nihon Rinsho. 2005 Apr;63(4):565-71.
8
Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.PPAR 调节在心血管疾病血管生成中的药理学作用。
Int J Mol Sci. 2023 Jan 25;24(3):2345. doi: 10.3390/ijms24032345.
9
Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.过氧化物酶体增殖物激活受体 (PPAR)β/δ，神经退行性疾病中 PPARα 和 PPARγ 依赖的分子途径的可能连接点：综述和新假说。
Neurochem Int. 2013 Oct;63(4):322-30. doi: 10.1016/j.neuint.2013.06.012. Epub 2013 Jun 25.
10
Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation.过氧化物酶体增殖物激活受体-β/δ 在炎症中的新兴作用。
Pharmacol Ther. 2009 Nov;124(2):141-50. doi: 10.1016/j.pharmthera.2009.06.011. Epub 2009 Jul 15.
引用本文的文献
1
Emerging Strategies for Targeting Angiogenesis and the Tumor Microenvironment in Gastrointestinal Malignancies: A Comprehensive Review.靶向胃肠道恶性肿瘤血管生成和肿瘤微环境的新兴策略：综述
Pharmaceuticals (Basel). 2025 Aug 5;18(8):1160. doi: 10.3390/ph18081160.
2
Neovascularization in Atherosclerotic Plaques: Clinical Implications, Detection, and Prevention Strategies.动脉粥样硬化斑块中的新生血管形成：临床意义、检测及预防策略
Rev Cardiovasc Med. 2025 Jul 23;26(7):36468. doi: 10.31083/RCM36468. eCollection 2025 Jul.
3
KAT2B regulates estradiol synthesis via H3K27ac/PPARα in granulosa cells of PCOS patients.KAT2B通过H3K27ac/PPARα调节多囊卵巢综合征患者颗粒细胞中的雌二醇合成。
J Transl Med. 2025 Jul 25;23(1):833. doi: 10.1186/s12967-025-06848-x.
4
Extracellular vesicles in pregnancy-related disorders: from mechanisms to clinical implications.妊娠相关疾病中的细胞外囊泡：从机制到临床意义
Sci China Life Sci. 2025 Jul 11. doi: 10.1007/s11427-024-2937-4.
5
Therapeutic potential of natural products in ischemic stroke: targeting angiogenesis.天然产物在缺血性脑卒中治疗中的潜力：靶向血管生成
Front Pharmacol. 2025 Jun 18;16:1579172. doi: 10.3389/fphar.2025.1579172. eCollection 2025.
6
Qing-Luo-Yin Eases T Cells-Mediated Angiogenesis in Adjuvant-Induced Arthritis Rats by Activating PPARγ.清络饮通过激活PPARγ减轻佐剂诱导性关节炎大鼠的T细胞介导的血管生成。
J Inflamm Res. 2025 Mar 10;18:3469-3484. doi: 10.2147/JIR.S508316. eCollection 2025.
7
Bio-nanocomplexes impair iron homeostasis to induce non-canonical ferroptosis in cancer cells.生物纳米复合物破坏铁稳态，从而在癌细胞中诱导非经典铁死亡。
J Nanobiotechnology. 2025 Feb 19;23(1):121. doi: 10.1186/s12951-025-03117-3.
8
Regulatory role of PPAR in colorectal cancer.过氧化物酶体增殖物激活受体（PPAR）在结直肠癌中的调节作用。
Cell Death Discov. 2025 Jan 28;11(1):28. doi: 10.1038/s41420-025-02313-2.
9
Unraveling the Molecular Mechanisms of SIRT7 in Angiogenesis: Insights from Substrate Clues.解析 SIRT7 在血管生成中的分子机制：来自底物线索的见解。
Int J Mol Sci. 2024 Oct 28;25(21):11578. doi: 10.3390/ijms252111578.
10
Lipid Storage, Lipolysis, and Lipotoxicity in Obesity.肥胖中的脂质储存、脂解和脂毒性。
Adv Exp Med Biol. 2024;1460:97-129. doi: 10.1007/978-3-031-63657-8_4.
本文引用的文献
1
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.过氧化物酶体增殖物激活受体及其新型配体作为非酒精性脂肪性肝病治疗的候选药物。
Cells. 2020 Jul 8;9(7):1638. doi: 10.3390/cells9071638.
2
Context-dependent regulation of endothelial cell metabolism: differential effects of the PPARβ/δ agonist GW0742 and VEGF-A.内皮细胞代谢的上下文依赖性调节：PPARβ/δ激动剂 GW0742 和 VEGF-A 的差异作用。
Sci Rep. 2020 May 12;10(1):7849. doi: 10.1038/s41598-020-63900-0.
3
PPAR Beta/Delta and the Hallmarks of Cancer.过氧化物酶体增殖物激活受体-β/δ 与癌症的特征。
Cells. 2020 May 4;9(5):1133. doi: 10.3390/cells9051133.
4
Vascular PPARβ/δ Promotes Tumor Angiogenesis and Progression.血管 PPARβ/δ 促进肿瘤血管生成和进展。
Cells. 2019 Dec 12;8(12):1623. doi: 10.3390/cells8121623.
5
PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.过氧化物酶体增殖物激活受体 α 配体 AVE8134 和环氧化酶抑制剂联合治疗协同抑制肺癌生长和转移。
BMC Cancer. 2019 Dec 2;19(1):1166. doi: 10.1186/s12885-019-6379-5.
6
The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis.过氧化物酶体增殖物激活受体-β/δ拮抗剂 GSK0660 减轻视网膜细胞炎症和白细胞淤滞。
Exp Eye Res. 2020 Jan;190:107885. doi: 10.1016/j.exer.2019.107885. Epub 2019 Nov 20.
7
8
Erratum to "Inducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta/Delta Leads to Rapid Cardiac Hypertrophy".《过氧化物酶体增殖物激活受体β/δ的诱导型条件性血管特异性过表达导致快速心脏肥大》勘误
PPAR Res. 2018 Oct 29;2018:5480829. doi: 10.1155/2018/5480829. eCollection 2018.
9
Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.PPARγ 激动剂罗格列酮诱导转移性黑素瘤细胞旁分泌信号激活基质细胞并增强肿瘤生长。
Cancer Res. 2018 Nov 15;78(22):6447-6461. doi: 10.1158/0008-5472.CAN-18-0912. Epub 2018 Sep 5.
10
Naoxintong restores collateral blood flow in a murine model of hindlimb ischemia through PPARδ-dependent mechanism.脑心通通过 PPARδ 依赖的机制恢复小鼠后肢缺血模型中的侧支血流。
J Ethnopharmacol. 2018 Dec 5;227:121-130. doi: 10.1016/j.jep.2018.08.032. Epub 2018 Aug 29.
Zotero 插件